ClinicalTrials.gg
CompletedNCT00620425Updated May 9, 2023Results posted

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

A Phase 1 interventional study of Sumatriptan in Healthy, sponsored by Zogenix, Inc.. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6 mg sumatriptan. Healthy Individuals will be enrolled for a series of 3 injections over 2 days. Assessment of Local Site Signs will be recorded for up to 5 days, as needed.

Read the detailed description

This study will evaluate the extent, persistence, and any cumulative effects on skin tissue by assessing local injection site reactions (bleeding, swelling, erythema, bruising) following repeated administrations of needle-free Intraject sumatriptan to the same anatomic site.

02

Conditions studied

  • Healthy

Keywords

  • sumatriptan
  • Intraject
  • Local Site Reactions
03

In context

Lead sponsor

Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Zogenix, Inc. became part of UCB S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects of must agree to use acceptable
  • Have abdominal or thigh injection sites that have sufficient subcutaneous tissue for needle-free injection
  • Fluent in the spoken and written English language
  • Provide written to participate in the study and be willing to comply with the study procedures
  • Non-tobacco user for at least 12 months prior to screening (all types of tobacco, including cigars)

Exclusion criteria

Exclusion Criteria:

  • A history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes including ischemic or vasospastic coronary artery disease
  • Other significant underlying cardiovascular diseases including uncontrolled hypertension
  • Hemiplegic or basilar migraine
  • A history or diagnosis of severe hepatic or renal impairment
  • A history of epilepsy or seizure or other serious neurologic condition
  • A history of allergy, anaphylaxis, or to sumatriptan or any of its components or similar drugs
  • A history of scleroderma (systemic sclerosis) or any skin condition that may adversely affect the injection or absorption of subcutaneously administered medications
  • Tattoos, birthmarks or other significant skin discoloration in the thigh or abdominal area that are large enough to restrict injection site selection and/or evaluation
  • Pregnancy or breast-feeding
  • Have participated in a clinical trial or receipt of an experimental therapy within 30 days prior to dosing
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Interventions

  • injection

    Also known as: SUMAVEL(R) DosePro(R)

06

What researchers measure

Primary outcomes

  1. The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).

    Each of the 18 participants were injected three times (for a total of 54 injections)with Sumavel DosePro, and followed over three days.

    Time frame: -15 min, immediately Post-dose, and 1, 4, 8, 24, 48 and 72 hrs post-dose

07

Results

Posted Jul 17, 2012

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started18
Completed18
Not completed0

Outcome measures

PrimaryThe Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).

Each of the 18 participants were injected three times (for a total of 54 injections)with Sumavel DosePro, and followed over three days.

Time frame:
-15 min, immediately Post-dose, and 1, 4, 8, 24, 48 and 72 hrs post-dose
Reported as:
Number · injections
The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).
injectionsAll Participants at -15 Min Pre-doseAll Participants Immediately Post-dose1 hr Post-dose4 hr Post-dose8 hr Post-dose24 hr Post-dose48 hr Post-dose72 hr Post-dose
Injections with Bleeding present051000000
Injections with Bruising present000134101
Injections with Swelling present0391800000
Injections with Erythema present093937181320

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants—0/18 (0%)6/18 (33.3%)
Most frequent other events
Most frequent other events
EventAll Participants
ParesthesiaNervous system disorders6/18
HeadacheNervous system disorders4/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years18
>=65 years0
Age, Continuous
Age, Continuous(years)All Participants
Mean31 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female13
Male5
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2008
First posted
Feb 21, 2008
Start
Dec 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jul 17, 2012
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00620425
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
Feb 21, 2008
Start date
Dec 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jul 17, 2012
Last update
May 9, 2023

Study contacts

Patricia Chandler, MD
principal investigator · Covance

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumatriptan

Start the discussion